Melanoma in a patient in treatment with eculizumab

Annals of Hematology

Volumn 91, Issue 1, 2012, Pages 135-136

  Manganoni, Ausilia Maria ^a   Pavoni, Laura ^a   Facchetti, Fabio ^a   Farisoglio, Camillo ^a   Sereni, Elena ^a   Calzavara Pinton, PierGiacomo ^a  

^a SPEDALI CIVILI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ECULIZUMAB; MONOCLONAL ANTIBODY;

ADULT; CANCER SURGERY; CASE REPORT; CLINICAL ARTICLE; CLINICAL EXAMINATION; COMPUTER ASSISTED TOMOGRAPHY; DYSPLASTIC NEVUS; ECHOGRAPHY; EPILUMINESCENCE MICROSCOPY; FEMALE; HUMAN; HUMAN TISSUE; LETTER; LYMPHOSCINTIGRAPHY; MELANOMA; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; PRIORITY JOURNAL; SENTINEL LYMPH NODE BIOPSY; CHEMICALLY INDUCED DISORDER; PATHOLOGY;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; FEMALE; HEMOGLOBINURIA, PAROXYSMAL; HUMANS; MELANOMA;

EID: 84857414346     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/s00277-011-1229-9     Document Type: Letter

References (6)

1. Hillmen P, Young NS, Schubert J et al (2006) The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med 355:1233-1243
2. Psaty EL, Scope A, Halpern AC, Marghoob AA (2010) Defining the patient at high risk for melanoma. Int J Dermatol 49(4):362-376
3. Balch CM, Gershenwald JE, Soong S, Thompson JF, Atkins MB, Byrd DR, Buzaid AC et al (2009) Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 27(36):6199-6206
4. Laroni A, Bedognetti M, Uccelli A, Capello E, Mancardi GL (2011) Association of melanoma and natalizumab therapy in the Italian MS population: a second case report. Neurol Sci 32(1):181-182
5. Wolfe F, Michaud K (2007) Biologic treatment of rheumatoid arthritis and risk of malignancy: analyses from a large US observational study. Arch Rheum 56:2886-2895
6. Askling J, Bongartz T (2008) Malignancy and biologic therapy in rheumatoid arthritis. Curr Opin Rheumatol 20:334-339